KRAS and lung adenocarcinoma: Indeed, using a KRAS-driven lung adenocarcinoma mouse model wherein both KRAS-G12D and deregulated MYC expression can be conditionally activated, the researchers present compelling evidence demonstrating the collaboration between these two oncogenes to instruct an immunosuppressive TIME.